| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Ch Sampanis | |
| P2860 | cites work | Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study | Q24652963 |
| Glycosylated haemoglobin in uraemia | Q68987985 | ||
| Similar risks of nephropathy in patients with type I or type II diabetes mellitus | Q69268410 | ||
| Splanchnic and renal metabolism of insulin in human subjects: a dose-response study | Q70261209 | ||
| Influence of erythropoietin treatment on glucose tolerance, insulin, glucagon, gastrin and pancreatic polypeptide secretion in haemodialyzed patients with end-stage renal failure | Q70284673 | ||
| Metabolic effects of exercise training in hemodialysis patients | Q70696394 | ||
| Effects of azotemia on results of the boronate-agarose affinity and ion-exchange methods for glycated hemoglobin | Q71350833 | ||
| Effect of Renal Disease on Renal Uptake and Excretion of Insulin in Man | Q71404542 | ||
| The relationship between glycemic control and morbidity and mortality for diabetics on dialysis | Q72282987 | ||
| Effects of intravenous calcitriol on lipid profiles and glucose tolerance in uraemic patients with secondary hyperparathyroidism | Q72588518 | ||
| Which diet for diabetic patients with chronic renal failure? | Q73114873 | ||
| Effect of Kimmelstiel-Wilson syndrome on insulin requirements in diabetes | Q73733691 | ||
| Tests of glycemia in diabetes | Q75205696 | ||
| Prevention Conference VI: Diabetes and Cardiovascular Disease: executive summary: conference proceeding for healthcare professionals from a special writing group of the American Heart Association | Q78057327 | ||
| Effect of pioglitazone on heart function and N-terminal pro-brain natriuretic peptide levels of patients with type 2 diabetes | Q80985309 | ||
| K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients | Q81607027 | ||
| Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group | Q27860882 | ||
| Decreased insulin requirement in acute renal failure in diabetic nephropathy | Q28331760 | ||
| Management of drugs affecting blood glucose in diabetic patients with renal failure. | Q33988958 | ||
| On the mechanism of impaired insulin secretion in chronic renal failure | Q34177471 | ||
| Renal filtration, transport, and metabolism of low-molecular-weight proteins: A review | Q34195953 | ||
| Metabolism of proinsulin, insulin, and C-peptide in the rat | Q34503792 | ||
| Standards of medical care in diabetes--2007. | Q34595288 | ||
| The pharmacology of sulfonylureas | Q34712872 | ||
| Assessing glycemic control in patients with diabetes and end-stage renal failure | Q35075910 | ||
| Glucose homeostasis and the kidney | Q35555064 | ||
| Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease | Q35907166 | ||
| Subcutaneous versus intraperitoneal insulin in the management of diabetics on CAPD: a review | Q36521280 | ||
| Hypoglycemia associated with renal failure. | Q38602967 | ||
| The renal metabolism of insulin | Q40192723 | ||
| Hydrolysis and transport of small peptides by the proximal tubule | Q40282883 | ||
| Diabetic nephropathy in type II diabetes | Q41003506 | ||
| Carbohydrate and insulin metabolism in renal failure | Q41626892 | ||
| Insulin influence (used as an additive to dialysate) on the mitogenic-induced effect of the peritoneal effluent in CAPD patients | Q42495193 | ||
| Impact of diabetic nephropathy on pharmacodynamic and Pharmacokinetic properties of insulin in type 1 diabetic patients | Q43603797 | ||
| Long-term glycemic control measurements in diabetic patients receiving hemodialysis | Q43882848 | ||
| Use of human ultralente as the basal insulin component in treatment of patients with IDDM. | Q43940972 | ||
| Hypoglycemia due to nateglinide administration in diabetic patient with chronic renal failure | Q44317938 | ||
| Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function | Q44333627 | ||
| Kinetics of glycosylated haemoglobin in uraemia determined on ion-exchange and affinity chromatography: no increase in the rate of glycosylation | Q44411154 | ||
| Decreased insulin requirement in relation to GFR in nephropathic Type 1 and insulin-treated Type 2 diabetic patients | Q44520349 | ||
| Pharmacokinetics of nateglinide and its metabolites in subjects with type 2 diabetes mellitus and renal failure. | Q44563042 | ||
| Mechanisms of impaired insulin secretion after chronic excess of parathyroid hormone | Q46043868 | ||
| Intravenous 1,25 dihydroxycholecalciferol corrects glucose intolerance in hemodialysis patients | Q46201467 | ||
| Abnormal leucine-induced insulin secretion in chronic renal failure | Q46222048 | ||
| Effect of recombinant human erythropoietin on insulin, amino acid, and lipid metabolism in uremia | Q46696779 | ||
| Dysglycaemia: a cardiovascular risk factor. | Q51568035 | ||
| Effects of erythropoietin on glucose tolerance in hemodialysis patients. | Q51592679 | ||
| A comparison of human ultralente- and lente-based twice-daily injection regimens. | Q51620184 | ||
| Glycosylated haemoglobin in renal failure. | Q51658760 | ||
| Effect of erythropoietin on the metabolic state and peripheral insulin sensitivity in diabetic patients on haemodialysis. | Q54252573 | ||
| Glucose and insulin metabolism in uremia. | Q54279650 | ||
| Intravenous calcitriol normalizes insulin sensitivity in uremic patients | Q62775804 | ||
| The spread of the obesity epidemic in the United States, 1991-1998 | Q64131265 | ||
| Spontaneous Hypoglycemia in End-Stage Renal Failure | Q66702354 | ||
| Insulin and the Kidney | Q66900424 | ||
| Abnormalities in circulating beta cell peptides in chronic renal failure: comparison of C-peptide, proinsulin and insulin | Q67676028 | ||
| Low protein and low phosphorus diet in patients with chronic renal failure: influence on glucose tolerance and tissue insulin sensitivity | Q68197315 | ||
| P433 | issue | 1 | |
| P921 | main subject | hyperglycemia | Q271993 |
| P304 | page(s) | 22-27 | |
| P577 | publication date | 2008-01-01 | |
| P1433 | published in | Hippokratia | Q26842167 |
| P1476 | title | Management of hyperglycemia in patients with diabetes mellitus and chronic renal failure | |
| P478 | volume | 12 |
| Q64231638 | Adult Nesidioblastosis in Chronic Kidney Disease |
| Q37391407 | In Silico Testing of an Artificial-Intelligence-Based Artificial Pancreas Designed for Use in the Intensive Care Unit Setting |
| Q26752692 | Management of anemia in patients with diabetic kidney disease: A consensus statement |
| Q26766259 | Management of diabetes mellitus in individuals with chronic kidney disease: therapeutic perspectives and glycemic control |
| Q38190465 | Saponin as regulator of biofuel: implication for ethnobotanical management of diabetes. |
Search more.